

Bedford MEMORIAL HOSPITAL

In Partnership
CARILION HEALTH SYSTEM &
CENTRA HEALTH

1613 Oakwood Street • Post Office Box 688 • Bedford, Virginia 24523-0688
Telephone 540-586-2441

March 1, 2008

NM582

US Nuclear Regulatory Commission
Division of Nuclear Materials Safety
Region I
475 Allendale Road
King of Prussia, PA 19406

Attention: Nuclear Materials Licensing Section

RE: Amendment Request to USNRC Radioactive Materials License No. 45-25627-01
(Docket No. 030-36291)

Dear Sirs:

Bedford Memorial Hospital (BMH) is requesting to amend our Radioactive Material License No. 45-25627-01 in the following manner:

- Revision to current license condition Number 12 – Licensed material is only authorized for use by or under the supervision of – to include the following additional individuals as Authorized Users (AUs)**

Authorized User	Material & Use	Training & Experience
Richard L. Newton, M.D.	By-product material listed under 10 CFR 35.100 & 35.200	Refer to attached copy of USNRC License No. 45-02207-01, Docket No. 030-03309, Licensee: Centra Health Corp., which lists Dr. Newton in Condition 12.B. as a previously approved AU for these two requested medical uses. His American Board of Radiology in Diagnostic Radiology certificate dated May 26, 1988 is attached, also.
Jeffrey S. Todd, M.D.	By-product material listed under 10 CFR 35.200	Refer to attached copy of USNRC License No. 45-25395-01, Docket No. 030-34470, Licensee: Carilion Clinic, which lists Dr. Todd in Condition 12.B. as a previously approved AU for this requested medical use. His original preceptor statements (Supplement B) & Nuclear Medical Education Program certificates from the Institute For Nuclear Medical Education, which were submitted previously for the above noted license, are attached, also.

RECEIVED
REGION I
2008 MAR 10 PM 1:28


Amendment Request to USNRC Radioactive Materials License No. 45-25627-01
(Docket No. 030-36291)
Bedford Memorial Hospital
March 1, 2008
Page 2 of 2

We feel that Dr. Richard L. Newton and Dr. Jeffrey S. Todd both fit the criteria of an experienced AU as defined in 10 CFR 35.57(b) for the above noted medical use of certain radioactive material at our licensed nuclear medicine facility.

- 2.) The following AU should be deleted from this license, since he's no longer associated with the licensee: David B. Truitt, M.D.

We remain available to provide additional and clarifying information and appreciate your prompt attention to this amendment request. Your contact person(s) for this matter is Jeffrey Messinger, RSO and he can be contacted at (540)981-7379 or via e-mail at rojgm1@carilion.com.

Respectfully submitted;



William Flattery, President & CEO
Bedford Memorial Hospital

Attachments: (4)

Pc: Judy Howard, CNT
Nuclear Medicine, BMH

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 5 PAGES
Amendment No. 70

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Centra Health Corporation</p> <p>2. 3300 Rivermont Avenue Lynchburg, Virginia 24503-2053</p>	<p>In accordance with the letters dated October 1 and 24, 2007,</p> <p>3. License number 45-02207-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date June 30, 2016</p> <hr/> <p>5. Docket No. 030-03309 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Strontium 90 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources [3M Health Physics Service Model 6500 Series; AEA Technology Model CDC.T1 (distributed by Medi-Physics, Inc.); New England Nuclear Model NER-8500 Series (distributed by Nuclear Associates, Inc. as 67-600 Series); Isotope Products Laboratories Model 67-800 Series (marketed as Nuclear Associates Model 67-824); Bard Brachytherapy, Inc. Model STM 1251; IsoAid LLC Model IAI-125A]</p> <p>E. Sealed Source [DuPont Merck Pharmaceutical Co. Model NB-1 (labeled as NEN)]</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1.5 curies</p> <p>D. 2 curies</p> <p>E. 100 millicuries</p>
--	--	---

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 5 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

45-02207-01

Docket or Reference Number

030-03309

Amendment No. 70

- | | | |
|---|---|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| F. Cesium 137 | F. Sealed Source (Amersham Corporation Model 77302) | F. 165 millicuries |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Strontium-90 for ophthalmic radiotherapy permitted by 10 CFR 35.400.
- F. For storage only in an Amersham/Tech Ops Model 773 calibrator.

CONDITIONS

- 10. A. Licensed material may be used or stored at the licensee's facilities located at Virginia Baptist Hospital, 3300 Rivermont Avenue, Lynchburg, Virginia.
- B. Licensed material in Items 6.A.-6.C. may be used or stored at the licensee's facilities located at Lynchburg General Hospital, 1901 Tate Springs Road, Lynchburg, Virginia.
- C. Licensed material limited to iodine-125 in Item 6.D. may be used or stored at Surgery Center of Lynchburg, 2401 Atherholt Road, Lynchburg, Virginia.
- 11. The Radiation Safety Officer for this license is Brian R. Hames, M.S.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Parham R. Fox, M.D.

35.100; 35.200; 35.300

Richard L. Newton, M.D.

35.100; 35.200; 35.300

Robert L. Green, M.D.

35.100; 35.200; 35.300

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 5 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-02207-01

Docket or Reference Number
030-03309

Amendment No. 70

<u>Authorized Users</u>	<u>Material and Use</u>
James L. Hall, Jr., M.D.	35.100; 35.200; 35.300
David B. Truitte, M.D.	35.200
Robert L. Driskill, M.D.	35.300; 35.400
Anita Joy Hilliard, M.D.	35.300; 35.400
John Alfieri, M.D.	35.100; 35.200
Carol Joy Darrah, M.D.	35.100; 35.200
David E. Johnsen, M.D.	35.100; 35.200; 35.300
Larry H. Redmond, M.D.	35.100; 35.200; 35.300
M. Camille Alexander, M.D.	35.100; 35.200
Kevin Oliver Hicks, M.D.	35.100; 35.200; 35.300
Adrian C. Moger, M.D.	35.100; 35.200; 35.300
Daniel W. Schepens, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131
Timothy B. Hellewell, M.D.	35.100; 35.200
Judith A. Perrotto, M.D.	35.100; 35.200
Kenneth C. Hite, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131; Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV

C. The following individual is an authorized medical physicist as indicated:

<u>Authorized Medical Physicists</u>	<u>Material and Use</u>
Brian R. Hames, M.S.	Strontium-90 ophthalmic source for physical decay calculations and calibrations; Cesium-137 calibrator in storage

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 5 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

45-02207-01

Docket or Reference Number

030-03309

Amendment No. 70

14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
 - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
 - F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
 - G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.
15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 of 5 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

45-02207-01

Docket or Reference Number

030-03309

Amendment No. 70

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 24, 2006 (ML060310659)
 - B. Letter dated May 31, 2006 (ML061520100)
 - C. Letter dated June 14, 2006 (ML061710555)

For the U.S. Nuclear Regulatory Commission

Date October 29, 2007

By

Original signed by Penny Lanzisera

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406

Monday, October 29, 2007 9:56:50 AM

The American Board of Radiology

*Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology,
and the Association of University Radiologists*

Hereby certifies that

Richard Lynn Newton, M.D.

*Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of*

The American Board of Radiology

On this twenty-sixth day of May, 1988

*Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of*


Diagnostic Radiology

M. Paul Capp, M.D.

President

James H. L. Ziegler, M.D.

Secretary



Official Use Only - Security-Related Information

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 7 PAGES
Amendment No. 21

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p align="center">Licensee</p> <p>1. Carilion Clinic c/o Department of Physics - CRMH</p> <p>2. Belleview and Jefferson Streets Roanoke, Virginia 24033</p>	<p>In accordance with the letters dated August 10 and September 12, 2007,</p> <p>3. License number 45-25395-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date April 30, 2013</p> <hr/> <p>5. Docket No. 030-34470 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (3M Models 6D6C and 6B6G; Best Medical Models 81-01, 81-02 and 2301; Medi-Physics Model 6711, North American Scientific Model MED-3631-A/M; Source Tech Model STM-1251; Mill Biopharmaceuticals Model I-125SL; Amersham Model SIA.20)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 7.5 curies total, not to exceed 1.5 curies per site</p> <p>D. 6 curies</p>
--	--	--

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

45-25395-01

Docket or Reference Number

030-34470

Amendment No. 21

- | | | |
|---|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| E. Any byproduct material permitted by 10 CFR 31.11 | E. Prepackaged Kits | E. 10 millicuries |
| F. Iridium-192 permitted by 10 CFR 35.600 | F. Sealed Sources (Varian Medical Systems Model VS-2000) | F. 13 curies per source and 21 curies total |
| G. Iodine 125 | G. Liquid Iotrex™ as part of the Gliasite® RTS System | G. 1320 millicuries per source and 5 curies total |
| H. Yttrium 90 | H. Any | H. 500 millicuries |
| I. Cesium 137 | I. Sealed Sources | I. 130 millicuries |
| J. Americium 241 | J. Sealed Source (Amersham Model 24400A) | J. 12 millicuries |
| K. Depleted Uranium | K. Solid metal blocks | K. 12 kilograms |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. In vitro studies.
- F. One source for medical use permitted by 10 CFR 35.600, in a Varian Medical Systems Model Varisource remote afterloader unit. The source activity may not exceed 10 curies at the time of medical use. One source in its shipping container as necessary for replacement of the source in the remote afterloader unit.
- G. For brachytherapy use in the Cytoc Surgical Products II Gliasite® RTS System.
- H. and I. For calibrations and checking of licensee's instruments.
- J. and K. For storage only incident to disposal.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-25395-01

Docket or Reference Number
030-34470

Amendment No. 21

CONDITIONS

10. A. Licensed material listed in Items 6.A. through 6.C. and 6.E. may be used or stored only at the licensee's facilities located at:

Carilion Roanoke Memorial Hospital (CRMH)
Bellevue at Jefferson Streets
Roanoke, Virginia

CRMH
Cancer Center of Western Virginia
2013 South Jefferson Street, S.W.
Roanoke, Virginia

Carilion Roanoke Community Hospital (CRCH)
101 Elm Street, S.E.
Roanoke, Virginia

CRMH
Rehabilitation Medical Center
2017 South Jefferson Street, S.W.
Roanoke, Virginia

Carilion New River Valley Medical Center
(CNRVMC)
2900 Tyler Road
Christiansburg, Virginia

- B. Licensed material listed in Item 6.D. and 6.G. may be used or stored only at the licensee's facilities located at CRMH.
- C. Licensed material listed in Items 6.F. and 6.H. through 6.K. may be used or stored only at the licensee's facilities located at CRMH - Cancer Center of Western Virginia, 2013 South Jefferson Street, S.W., Roanoke, Virginia.
- D. Licensed material listed in Item 6.B. may be used or stored only at the licensee's facilities located at Carilion Breast Care Center - Diagnostic (CBCC-D), Community Medical Office Building, Suite 202, 102 Highland Avenue, SE, Roanoke, Virginia.

11. The Radiation Safety Officer for this license is Jeffrey G. Messinger, M.E.

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-25395-01

Docket or Reference Number
030-34470

Amendment No. 21

B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
J. Bruce Hauser, M.D.	35.100; 35.200; 35.300; <i>in vitro studies</i>
James G. Mullet, M.D.	35.100; 35.200; 35.300; <i>in vitro studies</i>
Witold Brozyna, M.D.	35.100; 35.200; <i>in vitro studies</i>
Jeffrey Scott Todd, M.D.	35.200
Sudhendu Choubey, M.D.	35.200
Charles H. Warner, M.D.	35.100; 35.200; 35.300; <i>in vitro studies</i>
Bharat R. Patel, M.D.	35.100; 35.200; 35.300; <i>in vitro studies</i>
Donna Aubrey, M.D.	35.100; 35.200; 35.300; <i>in vitro studies</i>
Robert C. Heath, M.D.	35.300; 35.400; Iridium-192 for uses in a High Dose Rate Remote Afterloader Unit; Iodine-125 for use in the GliaSite® RTS System
Randal O. Hess, M.D.	35.300; 35.400; Iridium-192 for uses in a High Dose Rate Remote Afterloader Unit; Iodine-125 for use in the GliaSite® RTS System
Susan M. (Midcap) Sypolt, M.D.	35.100; 35.200; 35.300; <i>in vitro studies</i>
David A. Buck, M.D.	35.300; 35.400; Iridium-192 for uses in a High Dose Rate Remote Afterloader Unit
Granville Batte, M.D.	35.100; 35.200; 35.300
John W. Rogers, M.D.	35.400; Iridium-192 for uses in a High Dose Rate Remote Afterloader Unit
David A. Earl-Graef, M.D.	35.100; 35.200; 35.300

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 of 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-25395-01

Docket or Reference Number
030-34470

Amendment No. 21

C. The following individuals are authorized medical physicists as indicated:

Authorized Medical Physicists

Material and Use

Joseph L. Surace, M.S.

Strontium-90 in an eye applicator for decay calculations and calibrations; Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training

George Z. Kovats, M.Sc.

Strontium-90 in an eye applicator for decay calculations and calibrations; Iridium-192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training

D. The following individuals are authorized users for non-medical uses as indicated:

Users

Material and Use

Jeffrey G. Messinger, M.E.

Cesium 137 and Yttrium-90 for the calibration of instruments; Americium 241 and Depleted Uranium for storage only

Joseph L. Surace, M.S.

Cesium 137 and Yttrium-90 for the calibration of instruments

George Z. Kovats, M.Sc.

Cesium 137 and Yttrium-90 for the calibration of instruments

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 6 of 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-25395-01

Docket or Reference Number
030-34470

Amendment No. 21

- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
 - C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - D. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - E. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - F. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
 - G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
 - H. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.
15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 7 of 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-25395-01

Docket or Reference Number
030-34470

Amendment No. 21

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 10, 2003 (except Intravascular Brachytherapy Program) [ML030160575]
 - B. Letter dated January 28, 2003 [ML030300664]
 - C. Letter dated November 7, 2003 [ML033160534]
 - D. Letter dated January 10, 2005 [ML050340383]
 - E. Letter dated February 24, 2005 [ML050690408]
 - F. Letter dated March 8, 2006 [ML060820422]
 - G. Letter dated April 13, 2006 [ML061040242]
 - H. Letter dated March 22, 2007 [ML070880915]
 - I. Letter dated May 28, 2007 [ML071490488]

For the U.S. Nuclear Regulatory Commission

Date September 27, 2007

By




Sandra Gabriel
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406
Thursday, September 27, 2007 10:03:03 AM

EXHIBIT 3
SUPPLEMENT B


SUPPLEMENT		U. S. NUCLEAR REGULATORY COMMISSION	
PRECEPTOR STATEMENT			
Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.			
1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS FULL NAME Jeffrey S. Todd, M.D. STREET ADDRESS [REDACTED] CITY [REDACTED] STATE [REDACTED] ZIP CODE [REDACTED]		KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF: 1. Supervised examination of patients to determine the suitability for radioactive diagnosis and/or treatment and recommendation of prescribed dosage. 2. Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3. Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.	
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN			
ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
	Thyroid scan	0	THIS PRECEPTOR STATEMENT IS LIMITED TO CARDIAC NUCLEAR MEDICINE AND SUPPLEMENT B ONLY.
	Thyroid uptake	0	
	Lung perfusion scan	0	
	Xenon ventilation study	0	
	Aerosol ventilation scan	0	
	Renal flow scan	0	
	Brain scan	0	
	Liver/spleen scan	0	
	Bone scan	0	
	Gastroesophageal study	0	
	LeYeen shunt study	0	
	Cystogram	0	
	Dacryocystogram	0	
	Cardiac perfusion scan.	642	
	Cardiac stress ventriculogram	0	
Cardiac rest ventriculogram	27		
Gallium scan	0		

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER			
Jeffrey S. Todd, M.D.			
PRECEPTOR STATEMENT (Continued)			
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)			
ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS <small>(Additional information or comments may be submitted in duplicate on separate sheet.)</small> D
P-32 (Ga-67)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	105	THIS PRECEPTOR STATEMENT IS LIMITED TO CARDIAC NUCLEAR MEDICINE AND SUPPLEMENT B ONLY.
P-32 (Cs-137)	INTRACAVITARY TREATMENT	105	
I-131	TREATMENT OF THYROID CARCINOMA TREATMENT OF HYPERTHYROIDISM	105	
Au-198	INTRACAVITARY TREATMENT	105	
Co-60 or Cs-137	INTERSTITIAL TREATMENT INTRACAVITARY TREATMENT	105	
P-125 or Ir-192	INTERSTITIAL TREATMENT	105	
Co-60 or Cs-137	TELETERAPY TREATMENT	105	
Sr-90	TREATMENT OF EYE DISEASE RADIOPHARMACEUTICAL PREPARATION	105	
Mo-99/ Tc-99m	GENERATOR	40	
Sr-90/ Y-90	GENERATOR	0	
Tc-99m	REAGENT KITS	40	
Other	Patient Injections Computer Processing of Myocardial Perfusion	8 75	
3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING			
LOCATION		DATES	CLOCK HOURS OF EXPERIENCE
Pennsylvania State University Milton S. Hershey Medical Center Hershey, PA 17033		July 1, 1992 thru June 17, 1994	500
4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		5. PRECEPTOR'S SIGNATURE	
a. NAME OF SUPERVISOR Douglas F. Egli, M.D.		 Douglas F. Egli, M.D.	
b. NAME OF INSTITUTION Penn State/Hershey Medical Center			
c. MAILING ADDRESS Rm EG3002/P.O. Box 850			
d. CITY Hershey, PA 17033			
e. STATE LICENSE NUMBER 37-13831-01		f. DATE June 17, 1994	

EXH-7

For the Pennsylvania State University
Subcommittee on Human Use of Radioisotopes


Kenneth L. Miller, Secretary

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency


This document is to attest that
JEFFREY S. TODD, M.D.

has successfully completed the didactic program

RADIOPHARMACEUTICALS AND CHEMISTRY

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*additional documentation will be provided to Regulatory Agencies upon participant request

23 March 1994

Date Class Commenced


Authorized Signature

190102
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 800-548-4024

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency


This document is to attest that
JEFFREY S. TODD, M.D.

has successfully completed the didactic program

MEDICAL RADIATION PROTECTION

and has provided evidence of attendance in this program and evidence of achieving
the objectives of this program through examination.

This program provides the following levels of accomplishment:




- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*additional documentation will be provided to Regulatory Agencies upon
participant request

19 March 1994

Date Class Commenced


Authorized Signature

190336

Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 800-548-4024

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency

This document is to attest that


JEFFREY S. TODD, M.D.

has successfully completed the didactic program

MEDICAL RADIATION INSTRUMENTATION

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the American Pharmaceutical Association and the American Association of Health Physicists*

*additional documentation will be provided to Regulatory Agencies upon participant request

17 November 1993
Date Class Commenced


Authorized Signature

190449
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 800-548-4024

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency

This document is to attest that


JEFFREY S. TODD, M.D.

has successfully completed the didactic program

PRINCIPLES OF RADIATION PHYSICS

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*additional documentation will be provided to Regulatory Agencies upon participant request

13 November 1993
Date Class Commenced


Authorized Signature

190481
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 800-548-4024

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

June 1, 2008

Virginia Department of Health
Radiological Health
109 Governor Street, Room 730
Richmond, VA 23219
Attention: Radioactive Materials License Division

Subject: License amendment request
Ref: Radioactive Materials License Number VA-508-07

Bedford Memorial Hospital (BMH) is requesting amending our Virginia Department of Health – Radiological Health Program's Radioactive Materials (RAM) License Number VA-508-07 in the following manner:

1. In Condition 12.B. – Authorized Users (AUs)

We are requesting that the following two AUs for Material & Use of TI-201 be added to our license:

Richard L. Newton, M.D. and Jeffrey S. Todd, M.D.

Please refer to attached US NRC Radioactive Materials License Amendment No. , approval date , and a copy of our amendment request letters dated March 1, 2008 with attachments for detailed information regarding these requested changes to our VDH-RH RAM license.

Thank you for your prompt consideration of this matter. If you have any questions, please contact our consultant RSO Jeffrey G. Messinger at (540)981-7379 or e-mail him at rojgm1@carilion.com.

Respectfully submitted,

E. W. Tibbs, President & CEO
Bedford Memorial Hospital

Attachments (1)

This is to acknowledge the receipt of your letter/application dated

3/11/2008, and to inform you that the initial processing which includes an administrative review has been performed.

ALPHA 45-25627-01 There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 142186.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.